Cardiovascular diseases are still the major cause of death in the Western society and the main underlying pathology of cardiovascular disease is the development of atherosclerosis in the larger arteries.

At the division of Biopharmaceutics, it is our mission to develop and test new therapeutic approaches to limit or even prevent the development of atherosclerosis in order to reduce the number of acute cardiovascular syndromes such as myocardial infarction or stroke.

In Western society, cardiovascular diseases remain the major cause of death, which is caused by accumulation of lipids and inflammatory cells in the vessel wall resulting in the development of atherosclerosis.  Atherosclerosis is the process that leads to the narrowing of medium and large-sized arteries. The development of atherosclerotic plaques results from the complex interaction between lipids and lipoproteins, and the immune system.

At the division of Biopharmaceutics, we aim to elucidate the mechanisms underlying the development and progression of atherosclerosis, and use this information to develop novel therapeutic intervention strategies to halt the progression of atherosclerosis, stabilize the atherosclerotic plaque or even reverse plaque growth, leading to atherosclerotic plaque regression. Using these approaches we aim to develop novel therapies that can limit the incidence of acute cardiovascular syndromes, such as myocardial infarctions and strokes, in patients that suffer from cardiovascular diseases.